ロード中...
Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
The thiazolidinedione class peroxisome proliferator-activated receptor gamma (PPARγ) agonists are restricted in clinical use as antidiabetic agents because of side effects such as edema, weight gain, and heart failure. The single and selective agonism of PPARγ is the main cause of these side effects...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4232041/ https://ncbi.nlm.nih.gov/pubmed/25422585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S70383 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|